FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: Qantas in Talks to Buy 20 Jets From Boeing or Airbus

By

Qantas is in talks to possibly buy about 20 wide-body jets from Boeing (BA) or Airbus, Reuters reported Thursday, citing industry sources.

Specifically, the Australian airline is looking to purchase Boeing 787s or Airbus A350s, the report said, citing the sources.

The companies didn't immediately reply to requests for comment from.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: $217.94, Change: $+7.36, Percent Change: +3.50%

Related Articles

Wire

Qantas in Talks to Buy 20 Jets From Boeing or Airbus, Reuters Reports

Qantas in Talks to Buy 20 Jets From Boeing or Airbus, Reuters Reports

$BA
Wire

Update: Snap Acquires Augmented Reality Firm Illumix

(Updates with the company's comments throughout and latest stock move in the fifth paragraph.)Snap (SNAP) has acquired spatial augmented reality firm Illumix, a company spokesperson confirmed through email toThursday.Financial details related to the acquisition were not provided.Illumix's technology, platform, and the majority of its team members will join Snap to support AR efforts, including AR for Specs, the spokesperson said.Snap will continue to work with Illumix's existing customers and partners, including major theme parks, the spokesperson added.Shares of the company were up 4.5% in Thursday trading.Price: $5.99, Change: $+0.26, Percent Change: +4.45%

$SNAP
Wire

Update: Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case

(Updates with Amarin's response to a request for comment in the penultimate paragraph.)The US Supreme Court on Thursday ruled that Amarin (AMRN) failed to prove that a generic-drug manufacturer actively induced other companies to infringe upon two of its Vascepa patents after the generic maker received approval for a so-called "skinny-label" version of the drug.Vascepa received Food and Drug Administration approval in 2012 for treating severe hypertriglyceridemia before receiving the FDA's go-ahead in 2019 for a second, more common use: lowering cardiovascular risk in hypertriglyceridemia patients who take statins, the so-called CV indication, for which it received two patents, the Supreme Court noted.Hikma Pharmaceuticals received FDA approval for a generic icosapent ethyl skinny label in 2020 that carves out Vascepa's still-patented CV-indication method of use, the court noted."Amarin has failed to state a claim for active inducement in violation of *271(b), so its complaint cannot withstand Hikma's motion to dismiss," the Supreme Court said."We are deeply disappointed by the Supreme Court's decision today and are evaluating our next steps," Amarin toldin a statement. "Amarin remains fiercely dedicated to its primary mission: ensuring VASCEPA/VAZKEPA, a groundbreaking, innovative, and cost-effective therapy, reaches patients across the world who would benefit from this life-changing treatment."Hikma didn't immediately reply to a request for comment from.Price: $14.17, Change: $-0.36, Percent Change: -2.48%

$AMRN